see upsid consensu given comment last week
fundament improv see upsid guidanc also given quarterli
cadenc impli guid strong result increas view
current outlook prove pretti conserv despit recent move
like setup go qtr ep estimate
expect management provid updat sell season last qtr
stand net win report improv net loss
provid analyst day renew left unfinish
outperform comment call adjust price
underwrit pbm contract reflect lower drug inflat trend believ
indic headwind rebat guarante may eas convers
consult suggest success renegoti rebat guarante
true think would present upsid mgmt pbm guidanc
base recent employ trend survey see materi chang gross medic
cost trend expect corrobor unh comment survey
indic expect current yr medic cost trend appear rel consist
last yr plural respond expect y/i increas similar
last yr expect also fairli consist current yr prior yr
suggest us employ see expect materi chang gross
medic cost trend expect similar comment
expect management provid us updat healthhub strategi
perform open healthhub houston tx area recent trip one
healthhub left us posit view cvss strategi look comment
potenti uplift f-e sale margin given shift toward higher margin product
like dme addit look detail regard plan expans add
metropolitan area atlanta philadelphia tampa later yr
expect management provid updat synergi enterpris modern
program could indic whether mgmt medium- long-term guidanc rang
achiev last qtr management rais synergi target
higher end although remain unchang
earli stage execut enterpris modern effort expect
gener save beyond
believ guidanc may prove conserv particularli management rais adj
ep guidanc midpoint despit beat last qtr addit
guidanc guidanc impli unusu back-half quarterli progress
adj ep q/q even though typic strongest qtr yr
pleas see page report import disclosur
posit long-term strategi coordin care combin
legaci asset aet broader healthcar system continu transit toward
value-bas care believ potenti bring differenti model
market gain share and/or improv profit demonstr
valu proposit market management believ improv outcom lower cost
manag chronic condit use healthhub leverag telemedicin non-
physician provid furthermor view share under-valued current level
valuat suggest market assum overli pessimist outlook
detail regard mitig headwind
progress integr aet
merger achiev synergi target
increment inform l-t
strategi potenti revenu
top-lin growth primarili due
acquisit aet
adj oper margin modestli
y/i due higher margin profil
assum share repo
strong revenue growth due retail comp
slower expect rolloff
faster expect rollon
greater expect contribut
gener stronger expect
faster expect synergi ramp
lower expect invest
weak revenue growth due retail comp
faster expect rolloff
slower expect rollon
lower expect contribut
gener wors expect brand
slower expect synergi ramp
higher expect invest
one largest drug retail chain compani larg oper
two main busi segment pharmaci servic retail pharmaci
retail pharmaci segment compani oper drugstor on-line retail
pharmaci websit well health clinic store sell prescript drug
wide array gener merchandis refer front end product
compani also provid full rang pbm servic client mainli includ
organ sponsor health benefit plan servic includ formulari
servic diseas manag program pharmacogenom servic
expect manag provid anoth updat sell season
earn releas stand net win billion recal last quarter
report improv net loss sell season billion
billion provid analyst day june figur
improv sell season due gross new busi increas
million impact rolloff decreas million non-renew
decreas million result billion improv net loss
manag note last quarter renew left
figur sell season earn releas
billion
compani report cowen compani
figur sell season analyst day
billion
compani report cowen compani
comment recent earn call adjust price
underwrit pbm contract reflect lower drug inflat market trend
specif refer issu rebat guarante believ could
indic headwind rebat guarante may eas
look similar comment note convers consult
indic attempt make financi chang mid-contract cite
materi chang market due drug manufactur moder annual price
increas level success case think would present
upsid manag pbm guidanc mid-singl digit adj oper
incom growth provid analyst day june
expect manag provid updat regard medic cost trend base
recent employ trend survey see materi chang consolid
gross medic cost trend expect corrobor unh comment last
week survey indic expect current year medic cost trend appear
rel consist last year plural respond expect y/i increas
rang similar last year expect also fairli
consist current year prior year suggest us employ
see expect materi chang consolid gross medic cost trend
expect similar comment
expect manag provid updat healthhub strategi
perform three open healthhub houston texa area recent trip
one healthhub locat left us posit view cvss strategi overal
impress new format expect traffic profit metric benefit
mix-shift higher margin dme total sku even less
front-end squar footag replac health servic look comment
potenti uplift front-end sale margin given shift toward higher margin
product like dme end year expect healthhub locat
houston area addit look detail regard plan
expans addit metropolitan area atlanta philadelphia tampa later
year manag expect healthhub locat end
expect manag provid updat regard integr synergi
enterpris modern program could indic whether manag
medium- long-term guidanc rang achiev recal analyst day
manag note expect achiev low-singl digit adj ep growth
mid-singl digit adj ep growth low-doubl digit adj ep growth
beyond last quarter manag rais synergi target approxim
million higher end million million although
million synergi remain unchang figur earli stage
execut enterpris modern effort expect gener
save million million billion billion
beyond figur
million
compani report cowen compani
million
compani report cowen compani
believ guidanc may prove conserv particularli manag
rais adj ep guidanc top end bottom end
despit beat last quarter addit guidanc guidanc
impli unusu back-half quarterli progress adj ep q/q even
though typic strongest quarter year adj ep basi
expect moder q/q increas adj ep given hcb adj
oper profit decreas sequenti normal season increas medic
cost member work deduct well increas oper
expens due enrol cost sequenti pharmaci servic adj oper
profit growth flatten rel due pronounc impact
rolloff howev sequenti declin adj ep impli
modest sequenti growth retail/ltc adj oper profit recent year
better expect perform retail/ltc far year
progress impli guidanc seem less like view
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
see number risk associ drug retail space industri highli
competit retail drugstor chain independ pharmaci mail-ord provid
well retail includ groceri store mass merchant warehous club on-line
store compet space could pressur front-end sale margin
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind part believ
could concern around sustain high growth area
believ impact ppaca expect increas volum could subdu
depend implement execut
lack regulatori approv acquisit aet challeng
slower-than-expect onboard contract
